Video

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses the phase 3 ELEVATE-RR trial (NCT02477696) comparing the safety and efficacy of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). 

Results from the study showed no difference in efficacy between the 2 agents with regard to progression-free survival, according to Stephens. However, acalabrutinib showed a more favorable toxicity profile compared with ibrutinib in these patients, Stephens adds.

Acalabrutinib is a feasible option for this population, and its favorable toxicity profile may result in increased utilization of the agent, Stephens concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity